Get started Log in

SRNE — Sorrento Therapeutics Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Market Cap
$0.17m
Enterprise Value
$68.79m
Revenue
$62.84m

Brief: Caris Life Sciences, Prostate Cancer Clinical Trial Consortium And Sorrento Therapeutics To Collaborate
02/06/2022 11:48
Brief: Sorrento’s Partner, Lee’s Pharm, Announces Full Enrollment Of 498 Patients In A Phase III Trial Of Socazolimab
17/05/2022 19:59
Sorrento up on FDA clearance for cancer therapy trial
17/05/2022 16:53
Brief: Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data For Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-Her2-Adc, In Treating Heavily Pretreated Her2-Positive Breast Cancer Patients
03/05/2022 14:32
Sorrento up on completing enrollment in COVID treatment study
02/05/2022 15:43
Brief: Sorrento Announces Full Enrollment Of Phase I Study Of Intranasal STI-9199
02/05/2022 14:19
Brief: Sorrento Unit Appoints Elizabeth Czerepak As CFO
28/04/2022 14:36
Brief: Sorrento Reports FDA Authorization To Proceed With Phase 1 Study Of Intravenous STI-9167
25/04/2022 14:45
Brief: Sorrento Recieves FDA Clearance For Commencement Of Study For Abivertinib In Hospitalized Patients With Severe Pneumonia Due To COVID-19
31/03/2022 14:08
Brief: Scilex Holding A Majority-Owned Subsidiary Of Sorrento Therapeutics Enters Into A Non-Binding Term Sheet
25/03/2022 13:16
Brief: Sorrento Reports Promising Results With Universal Chimeric MRNA COVID Vaccine
20/03/2022 21:30
Brief: Dyadic International Inc Says Co And Sorrento Therapeutics Mutually Agreed To Terminate The Term Sheet
18/03/2022 20:26
Brief: Scilex Holding Co Announces Final Results For Sp-102 Semdexa Efficacy And Safety From Phase 3 Trial
18/03/2022 13:31
Brief: Scilex Holding Company, To Become Publicly Traded Through A Merger With Vickers Vantage Corp. I
17/03/2022 19:43
Sorrento up on FDA nod to start clinical study of COVID-19 treatment
02/03/2022 16:51
Brief: Sorrento Announces Covishield (Sti-9199) Antibody Nasal Drops Prevent Productive Sars-Cov-2 Infections When Given 24 Hours Prior To Virus Exposure
02/03/2022 16:39
Brief: Sorrento Announces FDA Authorization To Proceed With Phase 1 Study Of Intranasal STI-9199
02/03/2022 16:25
Brief: Sorrento Says Covishield (Sti-9167) Antibody Neutralizes BA.2 Omicron Sublineage Virus, Others
22/02/2022 14:24
Brief: Sorrento Acquires A Majority Ownership In Zhengzhou Fortune Bioscience
17/02/2022 18:04
Brief: Sorrento Therapeutics Inc - Borrowed $45.0 Million From Lender
16/02/2022 22:32